TriStar has a twelve-year track record supporting the drug discovery and companion diagnostic activities of leading pharmaceutical companies. Our resources include:
o Over 2.5 million archived human tumor tissue samples with extensive follow up and molecular data. Donors from Germany, Italy, Spain & the UK
o Longitudinal information
o Signal searching in various tumor types
o We offer a highly cost effective model by integrating our samples with analytical capabilities in IHC (Ventana, Dako & Leica Bond), RNAscope, Sanger & NGS (Illumina MiSeq, ThermoFisher S5) and RTPCR.
o Pathology expertise - 4 MD Pathologists
o Digital Image Analysis
FFPE blocks from prevalent tumor types (NSCLC, Bladder, Head & Neck, Pancreatic, Gastric, TNBC, RCC etc.) selected based on advancing tumor margin, qualitative assessment of inflammatory infiltrate and PDL1 by IHC staining (Ventana SP-263).
Control FFPE blocks (positive or negative) with matched double spun plasma - with follow up data:
o NSCLC: EGFR mutations (exon 19, 21 indels, variants), KRAS mutations, ALK (IHC), MSI (IHC), TIM3, LAG3, OX40, GITR, IDO1, PD-L1, PD-1, EGFR (amp)
o Melanoma: BRAF.V600E, TIM3, LAG3, OX40, GITR, IDO1, PD-L1, PD-1, MSI
Multi Tumor, Tumor-Specific & Normal Tissue Micro Arrays
o Multi Tumor TMA: over 500 cores from prevalent solid tumors and hematological cancers for screening targets of interest
o Normal TMA: over 100 cores from non-malignant tissues
o Tumor-Specific TMAs: prognosis arrays with treatment, response, survival information and molecular data
Selective biomarker stratification.
We have used sequencing and IHC in-house to stratify cohorts of samples for biomarker investigations and companion diagnostic development by our customers.
o CRC with KRAS, EGFR, NRAS, PIK3CA, BRAF, MSI
o Prostate cancers with PTEN (IHC & FISH).
o NSCLC, Bladder, Gastric, Small Bowel Carcinoma & RCC with known mismatch repair status (MSH-2,
MSH-6, MLH-1, PMS-2 - Ventana IHC).
o Specific TMAs (and FFPE blocks) in NHL, DLBCL, FL, MCL, AML, MDS, CLL with molecular and follow up data
Sample cohorts where response to "standard-of-care" and specific treatments is known. Non-responders are patients with unmet medical need.
o Sequential samples (FFPE, serum, plasma)
o TMAs with whole blocks in lung, prostate and CRC with single and double spun plasma for cross-validation studies.
Next Generation Sequencing (NGS) Services
TriStar Technology Group, LLC has not received any reviews.
TriStar Technology Group, LLC has not received any endorsements.